Shire gets injunction against Roche over hemophilia drug
Pharmaceutical group Shire (SHP.L) said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche (ROG.S) over its hemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment. Swiss drugmaker Roche is hoping to win a slice of the $11 billion-a-year hemophilia drug market with emicizumab, also known as ACE910 and designed to compete with more traditional treatments from Novo Nordisk (NOVOb.CO) and Shire.
Source:: https://finance.yahoo.com/news/shire-gets-injunction-against-roche-153449694.html
